Clinical trial
Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis…
NCT00130637 · National Eye Institute (NEI), NIH · Completed
Key facts
| NCT number | NCT00130637 |
|---|---|
| Title | Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis |
| Official title | Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab) |
| Lead sponsor | National Eye Institute (NEI), NIH |
| Collaborators | The Emmes Company, LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 6 |
| Start date | Aug 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Aug 15, 2005 |
| Last update posted | Jan 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: